QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: EMA Referral Implementation Across Product Information, RMP and Pharmacovigilance

Test your understanding of the concepts covered by How an EMA Referral Changes the SmPC, Package Leaflet and Risk Management Plan.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Following completion of an EU safety referral, what should the MAH determine first when planning implementation?

Which SmPC section contains the largest amount of safety information What final legally operative regulatory outcome was adopted and what requirements follow from it Whether the Package Leaflet can be updated without changing the SmPC Which internal department has previously managed similar label changes

Question 2 of 10 A referral confirms an important identified risk but leaves uncertainty about its incidence in a specific population. Which response is most conceptually appropriate?

Manage the established risk through appropriate product information while using further pharmacovigilance to address the remaining uncertainty Avoid mentioning the risk until the incidence is known precisely Classify the risk only as missing information and remove all warnings Use only an educational measure because identified risks cannot be studied further

Question 3 of 10 What is the most appropriate interpretation of the statement that a referral changes the baseline for future pharmacovigilance?

The referral permanently ends monitoring of the affected risk Future signals, aggregate assessments and risk-management decisions should take the newly authorised safety understanding into account All future safety reports must reproduce the referral assessment report The referral replaces routine pharmacovigilance with additional studies

Question 4 of 10 Which statement best describes the timing of RMP obligations after a referral?

They end once the revised SmPC is approved They apply only during the committee assessment phase They may continue through additional studies, effectiveness evaluation, signal monitoring and future RMP updates They are replaced by routine product-information maintenance

Question 5 of 10 Which statement best distinguishes the SmPC from the RMP?

The SmPC describes risk-monitoring studies, whereas the RMP defines authorised dosing The SmPC provides authorised professional information and conditions of use, whereas the RMP describes risks, uncertainties and how they are managed and monitored The SmPC is intended for patients, whereas the RMP is intended for prescribers The SmPC and RMP are interchangeable documents using different formats

Question 6 of 10 Which scenario best illustrates appropriate use of both routine product information and an additional pharmacovigilance activity?

A risk is sufficiently characterised and requires no communication or monitoring A serious risk is established enough to warrant a warning, but its frequency in an important subgroup remains uncertain A packaging typo is identified with no safety implications A company wants to conduct a study solely to justify broader contraindication wording

Question 7 of 10 What is the main reason an MAH should separate legally required implementation actions from voluntary internal governance actions?

Voluntary actions cannot be documented in the quality system The distinction clarifies which activities are imposed by the regulatory outcome and which are company controls, supporting accurate inspection interpretation Legally required actions do not need assigned owners Internal governance actions must always be implemented before regulatory actions

Question 8 of 10 Why might an RMP require substantial revision even when the immediate SmPC change is limited to a concise warning?

The RMP is required to reproduce every paragraph of the assessment report The RMP may need to address new safety concerns, residual uncertainties, studies or additional measures associated with the warning RMPs are automatically revised whenever any document changes, regardless of content A concise warning is legally invalid unless accompanied by a new clinical trial

Question 9 of 10 How should the wording in the SmPC, Package Leaflet and RMP relate after a referral?

It must be identical in every document Each document may contradict the others if it serves a different audience The wording may differ in form, but all documents must represent the same underlying regulatory conclusion The RMP should always contain less information than the Package Leaflet

Question 10 of 10 What is the key regulatory implication when the final assessment establishes that a medicine must not be used in a specified circumstance?

The circumstance should normally be considered for a contraindication in Section 4.3 The circumstance should be described only as an undesirable effect in Section 4.8 The circumstance should be added only to educational material The circumstance should be recorded only as missing information in the RMP

Knowledge Assessment: EMA Referral Implementation Across Product Information, RMP and Pharmacovigilance

Cookie Settings